Resveratrol Treatment of Autism Spectrum Disorder—A Pilot Study. Issue 5 (7th September 2022)
- Record Type:
- Journal Article
- Title:
- Resveratrol Treatment of Autism Spectrum Disorder—A Pilot Study. Issue 5 (7th September 2022)
- Main Title:
- Resveratrol Treatment of Autism Spectrum Disorder—A Pilot Study
- Authors:
- Marchezan, Josemar
Deckmann, Iohanna
da Fonseca, Guilherme Cordenonsi
Margis, Rogerio
Riesgo, Rudimar
Gottfried, Carmem - Abstract:
- Abstract : Objectives: Considering autism spectrum disorder (ASD) as a neurodevelopmental condition associated with immune system impairments, we aimed to evaluate the potential benefits, efficacy, tolerability, and safety of the anti-inflammatory, antioxidant, and neuroprotective trans -resveratrol (RSV) in behavioral impairments and in a set of 8 microRNAs (miR) related to the immune system in pediatric subjects with ASD. Methods: This is an open-label pilot trial over a 3 months (90 days) study follow-up period designed to assess the effect of 200 mg/d RSV on 5 boys aged 10 to 13 (11.8 ± 1.1) years diagnosed with ASD according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition . Results: The RSV treatment significantly reduced the Aberrant Behavior Checklist total score ( P = 0.042) and Irritability ( P = 0.041), with no alteration in Stereotypical Behavior ( P = 0.066), Hyperactivity ( P = 0.068), and Lethargy/Social Withdrawal ( P = 0.078) subscales. On the Clinical Global Impression scale, 3 individuals showed marked improvement in behavior; one showed mild improvement, and the other had no changes. The RSV treatment increased the miR-195-5p ( P = 0.043), an important modulator of targets related to inflammatory and immunological pathways. RSV administration did not present adverse effects and did not alter clinical laboratory results. Conclusions: RSV is a safe molecule for administrating in the pediatric population, able to modulate behaviorAbstract : Objectives: Considering autism spectrum disorder (ASD) as a neurodevelopmental condition associated with immune system impairments, we aimed to evaluate the potential benefits, efficacy, tolerability, and safety of the anti-inflammatory, antioxidant, and neuroprotective trans -resveratrol (RSV) in behavioral impairments and in a set of 8 microRNAs (miR) related to the immune system in pediatric subjects with ASD. Methods: This is an open-label pilot trial over a 3 months (90 days) study follow-up period designed to assess the effect of 200 mg/d RSV on 5 boys aged 10 to 13 (11.8 ± 1.1) years diagnosed with ASD according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition . Results: The RSV treatment significantly reduced the Aberrant Behavior Checklist total score ( P = 0.042) and Irritability ( P = 0.041), with no alteration in Stereotypical Behavior ( P = 0.066), Hyperactivity ( P = 0.068), and Lethargy/Social Withdrawal ( P = 0.078) subscales. On the Clinical Global Impression scale, 3 individuals showed marked improvement in behavior; one showed mild improvement, and the other had no changes. The RSV treatment increased the miR-195-5p ( P = 0.043), an important modulator of targets related to inflammatory and immunological pathways. RSV administration did not present adverse effects and did not alter clinical laboratory results. Conclusions: RSV is a safe molecule for administrating in the pediatric population, able to modulate behavior alterations and molecules associated with the immune system, becoming a promising therapeutic strategy for large-scale studies in ASD, to investigate both behavioral and molecular approaches. … (more)
- Is Part Of:
- Clinical neuropharmacology. Volume 45:Issue 5(2022)
- Journal:
- Clinical neuropharmacology
- Issue:
- Volume 45:Issue 5(2022)
- Issue Display:
- Volume 45, Issue 5 (2022)
- Year:
- 2022
- Volume:
- 45
- Issue:
- 5
- Issue Sort Value:
- 2022-0045-0005-0000
- Page Start:
- 122
- Page End:
- 127
- Publication Date:
- 2022-09-07
- Subjects:
- autism spectrum disorder -- ASD -- inflammation -- resveratrol -- neuroinflammation -- neuroprotection
Neuropharmacology -- Periodicals
615.78 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00002826-000000000-00000 ↗
http://journals.lww.com/clinicalneuropharm/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/WNF.0000000000000516 ↗
- Languages:
- English
- ISSNs:
- 0362-5664
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.310600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23938.xml